Argus
•
Jun 18, 2026
Illumina, Inc.: Raising target to $180
Summary
Illumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company’s products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses.
The company’s portfolio of products and services is designed to accelerate and simplify genetic analysis. Illumina also invests
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus’ bespoke research on IPOs.
